Valuation: Kodiak Sciences Inc.

Market Cap 2.05B 1.79B 1.69B 1.53B 2.87B 197B 2.89B 20.24B 7.81B 100B 7.71B 7.54B 322B P/E 2026 *
-8.2x
P/E 2027 * -8.73x
Enterprise Value 1.89B 1.65B 1.56B 1.41B 2.65B 181B 2.66B 18.63B 7.19B 92.15B 7.1B 6.94B 296B EV / Sales 2026 *
-
EV / Sales 2027 * 54.3x
Free-Float
94.84%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week-0.55%
Current month-12.42%
1 month-17.90%
3 months-9.49%
6 months+47.01%
Current year+16.99%
1 week 31.54
Extreme 31.54
33.69
1 month 31.54
Extreme 31.54
40.11
Current year 20.88
Extreme 20.88
47.84
1 year 9.8
Extreme 9.8
47.84
3 years 1.37
Extreme 1.37
47.84
5 years 1.37
Extreme 1.37
131.97
10 years 1.37
Extreme 1.37
171.21
Manager TitleAgeSince
Chief Executive Officer 53 01/01/2009
Director of Finance/CFO 64 01/01/2016
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Chairman 53 01/01/2009
Director/Board Member 57 01/09/2015
Director/Board Member 55 18/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

Chief Executive Officer

100,000 0.1598%
15/07/26 Free

Chief Financial Officer

66,500 0.1063%
30/06/26 Free

Director

17,731 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-0.55%+243.23%+1,465.07% 2.05B
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+0.50%+7.13%+33.27%+20.02% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average -0.24%+1.51%+57.24%+337.25% 27.69B
Weighted average by Cap. -0.28%+1.47%+37.22%+160.56%

Financials

2026 *2027 *
Net sales - 34.4M 30M 28.32M 25.72M 48.19M 3.3B 48.39M 339M 131M 1.68B 129M 126M 5.4B
Net income -260M -227M -214M -194M -364M -24.93B -365M -2.56B -989M -12.67B -976M -954M -40.78B -268M -234M -221M -201M -376M -25.75B -377M -2.65B -1.02B -13.09B -1.01B -986M -42.12B
Net Debt -163M -142M -134M -122M -228M -15.63B -229M -1.61B -620M -7.94B -612M -598M -25.56B -183M -160M -151M -137M -256M -17.57B -258M -1.81B -697M -8.93B -688M -672M -28.73B
Logo Kodiak Sciences Inc.
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Employees
141
Date Price Change Volume
18/09/26 $32.71 -0.43% 1,608,964
17/09/26 $32.85 +0.24% 826,147
16/09/26 $32.77 -0.67% 707,944
15/09/26 $32.99 -0.45% 819,594
14/09/26 $33.14 +0.76% 547,793
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
32.71USD
Average target price
69.60USD
Spread / Average Target
+112.78%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!